对ACCORD强化降糖治疗有反应的2型糖尿病亚型
该研究基于ACCORD随机对照试验,通过聚类HbA1c轨迹在强化降糖组中识别出四个临床分组,其中C4组的心血管疾病风险(HR 0.34)和微血管结局风险(HR 0.86)低于标准治疗组。多基因评分可高准确度预测C4组(AUC 0.98),且预测的C4组在强化治疗下心血管风险降低(HR 0.53),孟德尔随机化提示因果关系。
要点
- ACCORD强化降糖组中存在C4亚组,其心血管和微血管结局风险低于标准治疗。
- 多基因评分可高准确度预测C4组,预测C4组强化治疗心血管风险降低。
- 孟德尔随机化提示多基因评分、HbA1c降低与心血管结局减少存在因果关系。
核心结论
- ACCORD试验中部分2型糖尿病患者可从强化降糖治疗中获益,该亚组可通过遗传变异预测。
研究设计与样本
- ACCORD随机对照试验,比较强化降糖与标准治疗对2型糖尿病患者心血管结局的影响。
- 采用新型HbA1c轨迹聚类方法在强化降糖组中识别临床分组。
- 进行全基因组分析和多基因评分构建以预测分组归属。
- 采用孟德尔随机化推断因果关系。
主要发现
- 在强化降糖组中识别出四个临床分组。
- 临床分组4(C4)的心血管疾病风险低于标准治疗组(HR 0.34;P = 2.01 × 10-3)。
- C4组的微血管结局风险低于标准治疗组(HR 0.86;P = 0.015)。
- 单核苷酸多态性rs220721在MAS1基因达到提示性显著(P = 4.34 × 10-7)。
- 多基因评分预测C4组准确度高(AUC 0.98),预测C4组强化治疗心血管风险降低(HR 0.53;P = 4.02 × 10-6),但微血管结局风险未降低(P < 0.05)。
关键数值与推荐
- C4组心血管疾病风险HR 0.34(P = 2.01 × 10-3)。
- C4组微血管结局风险HR 0.86(P = 0.015)。
- 预测C4组强化治疗心血管风险HR 0.53(P = 4.02 × 10-6)。
- 多基因评分预测C4组AUC 0.98。
- rs220721在C4组P = 4.34 × 10-7。
临床怎么用
- 提示对2型糖尿病强化降糖治疗的反应存在异质性,部分患者可能获益。
- 遗传变异预测的亚组识别可能为精准医学提供新思路。
- 当前发现尚属假设生成,需进一步研究验证后方可用于临床决策。
局限性
- 研究结果为假设生成性质,需进一步研究验证。
- 原文未报告样本量等详细局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response to intensive glycemia treatment has been observed, suggesting potential benefit for some individuals. RESEARCH DESIGN AND METHODS: ACCORD was a randomized controlled trial that investigated whether intensively treating glycemia in individuals with T2D would reduce CVD outcomes. Using a novel approach to cluster HbA1c trajectories, we identified groups in the intensive glycemia arm with modified CVD risk. Genome-wide analysis and polygenic score (PS) were developed to predict group membership. Mendelian randomization was performed to infer causality. RESULTS: We identified four clinical groupings in the intensive glycemia arm, and clinical group 4 (C4) displayed fewer CVD (hazard ratio [HR] 0.34; P = 2.01 × 10-3) and microvascular outcomes (HR 0.86; P = 0.015) than those receiving standard treatment. A single-nucleotide polymorphism, rs220721, in MAS1 reached suggestive significance in C4 (P = 4.34 × 10-7). PS predicted C4 with high accuracy (area under the receiver operating characteristic curve 0.98), and this predicted C4 displayed reduced CVD risk with intensive versus standard glycemia treatment (HR 0.53; P = 4.02 × 10-6), but not reduced risk of microvascular outcomes (P < 0.05). Mendelian randomization indicated causality between PS, on-trial HbA1c, and reduction in CVD outcomes (P < 0.05). CONCLUSIONS: We found evidence of a T2D clinical group in ACCORD that benefited from intensive glycemia treatment, and membership in this group could be predicted using genetic variants. This study generates new hypotheses with implications for precision medicine in T2D and represents an important development in this landmark clinical trial warranting further investigation.
引用
- Mariam A, Miller-Atkins G, Pantalone KM, et al. A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. Diabetes Care. 2021. PMID: 33863751. doi:10.2337/dc20-2700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。